Abstract

The target of research was the implementation of the comparative analysis of conservative therapy of preparation of basic therapy and also new methods of treatment (anticytokine therapy). Appointment of salofalk - in twos tablets (0, 5) 3-4 times a day per os, and also 2,0 gr in the form of a rectal enema unitary for a period of seven days, then had transferd the patients to reception 2,0 gr salofalk per os, allowed to achieve substantial improvement patients’ clinic-laboratory and endoscopic symptoms with a heavy intensification of ulcer colitis variation, providing full clinic-labaratory remissions achievements of disease at 8 (34 %) patients. In the Minister of the Uzbek Public Health of the Republican Science Coloproctological Center at 10 patients with the IDI have spent the therapy remicade, 7 of them had NUC and 3 patients had the Crohn's disease. Therefore, all patients no longer than on the first week after introduction of remicade had improvement of a course disease which was expressed in defering stool, extinction or reduction of pathological impurity in excrement and subsidence bellyaches. During colonoscopical inspection, in 12-18 weeks after the first infusion at 80% of the patients had observed disappearance of ulcers and erosion. In terms of 6 months of supervision of relapse of disease was not noted. All new directions in treatment of the IDI, apparently, are perspective, but while are proved only theoretically and had no practical development. Unique and enough effective and safe method at the IDI and already has clinical acknowledgement is remicade.

Highlights

  • The fundamental moment in immunopathogenesis of the inflammatory diseases of intestines (IDI) is predominance of proinflammatory cytokine (IL­1, TNF ­ α, IF­y, chemokinesis, IL 6, IL 7, IL 12, IL 16, IL 17, IL 18) over antiinflammatory (IL 4, IL 10, IL 11, IL 13, the transforming factor of growth β)

  • Among cytokines with inflammatory action one of the most active is FNO ­ α. It is considered as the key in the course of inflammation. This cytokine exists in two kinds: in the transmembrane form and in the form of soluble trim tab

  • Insufficient efficiency of existing basic therapy of the IDI and necessity of improvement the results of conservative treatment of these diseases, overcoming of steroid resistance put in the forefront searches of new approaches on therapy [2]

Read more

Summary

Introduction

The fundamental moment in immunopathogenesis of the IDI is predominance of proinflammatory cytokine (IL­1, TNF ­ α, IF­y, chemokinesis, IL 6, IL 7, IL 12, IL 16, IL 17, IL 18) over antiinflammatory (IL 4, IL 10, IL 11, IL 13, the transforming factor of growth β). ■ 613.3 ■ CROHN'S DISEASE■ NONSPECIFIC ULCEROUS COLITIS ■ SALOFALK ■ REMICADE ■

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call